Leucht, S, Pitschel-Walz, G, Abraham, D, Kissling, W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res
1999; 35: 51–68.
Leucht, S, Tardy, M, Komossa, K, Heres, S, Kissling, W, Salanti, G, Davis, JM. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet
2012; 379: 2063–71.
Leucht, S, Cipriani, A, Spineli, L, Mavridis, D, Orey, D, Richter, F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet
2013; 382: 951–62.
Crossley, NA, Constante, M, McGuire, P, Power, P. Efficacy of atypical v. typical antipsychotics in the treatment of early psychosis: meta-analysis. Br J Psychiatry
2010; 196: 434–9.
Fraguas, D, Correll, CU, Merchan-Naranjo, J, Rapado-Castro, M, Parellada, M, Moreno, C, et al. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons. Eur Neuropsychopharmacol
2011; 21: 621–45.
Zhang, JP, Gallego, JA, Robinson, DG, Malhotra, AK, Kane, JM, Correll, CU. Efficacy and safety of individual second-generation vs first-generation antipsychotics in first episode psychosis: a systematic review and meta-analysis. Int J Neuropsycho-pharmacol
2013; 16: 1205–18.
Alvarez-Jimenez, M, Gonzalez-Blanch, C, Crespo-Facorro, B, Hetrick, S, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, et al. Antipsychotic-induced weight gain in chronic and first-episode psychotic disorders: a systematic critical reappraisal. CNS Drugs
2008; 22: 547–62.
Streiner, DL. Statistics commentary series: commentary #6 – are trial participants representative of ‘real’ patients. J Clin Psychopharm
2015; 35: 4–6.
Lieberman, J, Stroup, T, McEvoy, J, Swartz, MS, Rosenheck, RA, Perkins, DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Kahn, RS, Fleischhacker, WW, Boter, H, Davidson, M, Vergouwe, Y, Keet, IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet
2008; 371: 1085–97.
Lewis, SW, Barnes, TR, Davies, L, Murray, RM, Dunn, G, Hayhurst, KP, et al. Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull
2006; 32: 715–23.
McEvoy, JP, Lieberman, JA, Perkins, DO, Hamer, RM, Gu, H, Lazarus, A, et al. Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry
2007; 164: 1050–60.
Johnsen, E, Kroken, RA, Wentzel-Larsen, T, Jørgensen, HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone. BMC Psychiatry
2010; 10: 26.
Crespo-Facorro, B, Perez-Iglesias, R, Mata, I, Ramirez-Bonilla, M, Martínez-Garcia, O, Pardo-Garcia, G, et al. Effectiveness of haloperidol, risperidone and olanzapine in the treatment of first-episode non-affective psychosis: results of a randomized, flexible-dose, open-label 1-year follow-up comparison. J Psychopharmacol
2011; 25: 744–54.
San, L, Arranz, B, Perez, V, Safont, G, Corripio, I, Ramirez, N, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychInaive patients with a first-episode psychosis. Psychiatry Res
2012; 200: 693–701.
Tiihonen, J, Haukka, J, Taylor, M, Haddad, PM, Patel, MX, Korhonen, P. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry
2011; 168: 603–9.
Liew, A, Verma, S, Lye Yin, P, Edimansyah, A, Subramaniam, M, Vaingankar, J, et al. Comparing effectiveness of risperidone with first-generation antipsychotic medications in patients with schizophrenia-spectrum disorders. J Psychopharmacol
2010; 24: 973–80.
Olfson, M, Gerhard, T, Huang, C, Lieberman, JA, Bobo, WV, Crystal, S. Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull
2012; 38: 845–53.
Lieberman, JA, Stroup, TS, McEvoy, JP, Swartz, MS, Rosenheck, RA, Perkins, DO. Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med
2005; 353: 1209–23.
Early Psychosis Guidelines Writing Group and EPPIC National Support Program. Australian Clinical Guidelines for Early Psychosis (2nd edn, ). Orygen, The National Centre of Excellence in Youth Mental Health, 2016.
Young, SL, Taylor, M, Lawrie, SM. ‘First do no harm’. A systematic review of the prevalence and management of antipsychotic adverse effects. J Psychopharmacol
2015; 29: 353–62.
Hill, M, Crumlish, N, Clarke, M, Whitty, P, Owens, E, Renwick, L, et al. Prospective relationship of duration of untreated psychosis to psychopathology and functional outcome over 12 years. Schizophr Res
2012; 141: 215–21.
Levine, SZ, Leucht, S. Delayed- and early-onset hypotheses of antipsychotic drug action in the negative symptoms of schizophrenia. Eur Neuropsychopharmacol
2012; 22: 812–7.
Crespo-Facorro, B, Pérez-Iglesias, R, Mata, I, Martínez-Garcia, O, Ortiz, V, Pelayo-Terán, JM, et al. Long-term (3-year) effectiveness of haloperidol, risperidone and olanzapine: results of a randomized, flexible-dose, open-label comparison in first-episode nonaffective psychosis. Psychopharmacology
2012; 219: 225–33.
Simmons, MB, Hetrick, SE. ‘Prodromal’ research and clinical services: The imperative for shared decision-making. Aust N Z J Psychiatry
2012; 46: 66.
Whale, R, Pereira, M, Cuthbert, S, Fialho, R. Effectiveness and predictors of continuation of paliperidone palmitate long acting injection treatment: a 12 month naturalistic cohort study. J Clin Psychopharm
2015; 35: 591–5.
Subotnik, KL, Casaus, LR, Ventura, J, Luo, JS, Hellemann, GS, Gretchen-Doorly, D, et al. Long-acting injectable risperidone for relapse prevention and control of break-through symptoms after a recent first episode of schizophrenia. A randomized clinical trial. JAMA Psychiatry
2015; 72: 822–9.